The nuclear translocation of SERPINA3 during anti-estrogen therapy and the resulted benign prognostic effect make sense of the negative role of SERPINA3 in AI resistance development in ER+ breast cancer. The gene discussed is SERPINA3; the disease is breast carcinoma.